Ryan Hasselkus

Ryan Hasselkus

Auto-generated profile, based on publicly available information

Ryan Hasselkus

Quris Technologies INC., 38 Wareham St., Boston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TPTae-Eun Park
Tae-Eun Park
Nur MustafaogluNur Mustafaoglu
Nur Mustafaoglu
AHAnna Herland
Anna Herland
RHRyan Hasselkus
Ryan Hasselkus
RMRobert Mannix
Robert Mannix
DIDonald E Ingber
Donald E Ingber
The high selectivity of the human blood-brain barrier (BBB) restricts delivery of many pharmaceuticals and therapeutic antibodies to the central nervous system. Here, we describe an in vitro microfluidic organ-on-a-chip BBB model lined by induced pluripotent stem cell-derived human brain microvascular endothelium interfaced with primary human brain astrocytes and pericytes that recapitulates the high level of barrier function of the in vivo human BBB for at least one week in culture. The endothelium expresses high levels of tight junction proteins and functional efflux pumps, and it displays selective transcytosis of peptides and antibodies previously observed in vivo. Increased barrier functionality was accomplished using a developmentally-inspired induction protocol that includes a period of differentiation under hypoxic conditions. This enhanced BBB Chip may therefore represent a new in vitro tool for development and validation of delivery systems that transport drugs and therapeutic antibodies across the human BBB.

4 April 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
WWWei Wu
Wei Wu
FAFaiza Anas
Faiza Anas
BKBaran Koc
Baran Koc
LTLipeng Tian
Lipeng Tian
RHRyan Hasselkus
Ryan Hasselkus
ABAmir Bein
Amir Bein
Accurate prediction of drug toxicity is a major challenge for therapeutic development. The use of animal models for predicting toxicity has been a longstanding practice, but often falls short in accurately predicting human-specific responses. Human in vitro models, such as organoids and spheroids, provide alternative approaches to animal models. In this study, we employed primary human-derived liver spheroids (hLiSps) and human induced pluripotent stem cells (iPSC)-derived brain organoids (hiBOs) to create a combined Liver+Brain model for neurotoxicity assessment, to investigate the potential influence of incorporating a liver preconditioning component on toxic responses in the brain. Comparing the effect of six example drugs that are known to cause adverse clinical neurological effects, we observed that troglitazone (Trgl), tested at clinically relevant doses in the Liver+Brain model, caused a significantly greater reduction in cell viability compared to similar treatments in the Brain-only model. This was further confirmed across multiple donors and various stages of brain organoid development. In contrast, we found that high dose valproic acid treatment increased cell viability in the Liver+Brain model. Transcriptome analysis using RNA-seq revealed that liver-preconditioned Trgl elicited a more pronounced transcriptional response in hiBOs, identifying a 7-fold increase in the number of affected genes and over a 10-fold increase in affected pathways containing gene set components specifically associated with cell division and neurogenesis, which were not observed in the Brain model. Taken together, our data suggest that the addition of hLiSps to hiBOs is critical to accurately assess neurotoxicity using a comprehensive human in vitro model.

21 August 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
LTLipeng Tian
Lipeng Tian
FAFaiza H. Anas
Faiza H. Anas
RHRyan Hasselkus
Ryan Hasselkus
EJElsa Joseph
Elsa Joseph
MCMichelle Chadraa
Michelle Chadraa
ABAmir Bein
Amir Bein
Drug-induced liver injury remains a leading cause of drug development failure and a major clinical safety concern. Human induced pluripotent stem cell–derived hepatocytes offer a promising approach for modeling patient-specific drug responses, but their immature phenotype limits predictive performance. We report a chemically defined six-compound maturation strategy for human stem cell–derived liver spheroids. Matured spheroids acquire adult-like hepatic features, including increased cytochrome P450 activity, enhanced metabolic capacity, and a metabolic shift toward oxidative phosphorylation, supported by genome-wide pathway analysis and functional assays across multiple donors. When evaluated with twenty reference compounds, matured spheroids improve hepatotoxicity prediction and outperform primary human hepatocyte spheroids. Free fatty acids treatment further induces features of metabolic dysfunction-associated steatotic liver disease and increases sensitivity to selected hepatotoxic drugs. In this work, we show that a defined six-compound cocktail enhances stem cell-derived liver spheroids maturation, improves drug-induced hepatotoxicity prediction, and enables modeling of steatotic liver disease.